Takeda's Deal to Buy Valeant's Salix Falls Apart

Nov 30, 2016

Bloomberg

After early reports that Takeda Pharmaceutical's negotiations to buy Valeant's Salix stomach-drug biz were breaking down over price, Bloomberg has reported that Valeant will keep its Salix business.

Earlier this month, news sources reported that Valeant was in advanced talks to sell its Salix business to Japan’s Takeda for about $10 billion.

The sale fallout will put increased pressure on Valeant to find a way to settle its $30 billion debt.

Valeant announced in a press release on Tuesday that it was making a “significant” expansion in the size of the sales force for two Salix products, gastrointestinal treatment Xifaxan and constipation treatment Relistor.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments